Immune system
An oral immune-support medicine used in Europe and Asia to cut down recurring respiratory infections, especially in children.
Start here
Pidotimod is a lab-made dipeptide — two linked amino acids — taken by mouth to strengthen the immune system. It is studied mainly for cutting how often recurrent respiratory infections strike and how long they last, and it works by activating the immune cells that detect invaders and coordinate the body's response. It has moderate human trial evidence (Phase 1-2) and is classed as a research compound, not an FDA-approved medicine.
Pidotimod is a synthetic dipeptide (threonyl-lysine) that activates immune cells and helps restore normal immune function. It works by enhancing T cell and B cell activity, increasing antibody production, and promoting immune cell communication. It's used to strengthen immunity in people with weak immune systems or during chronic infections.
Pidotimod is a two-amino-acid peptide (a dipeptide, L-threonyl-L-lysine). It activates immune cells by engaging peptide-recognition receptors (sensors that spot peptides) on T cells and antigen-presenting cells (immune cells that show pieces of germs to other immune cells). The peptide boosts the development of T helper (Th1) cells (immune cells that fight germs living inside cells) through IL-12 signaling (an immune messenger). It also raises production of IFN-γ (interferon-gamma, an immune messenger), which supports cellular immunity (defense by immune cells) against germs that hide inside cells. At the same time, pidotimod promotes the development of Th17 cells (immune cells that guard mucous linings) through IL-6/STAT3 signaling, which strengthens mucosal immunity (defense of linings such as the airways and gut). The peptide increases growth of CD4+ and CD8+ T cells (two kinds of immune cells) by raising IL-2 receptor levels and IL-2 signaling (an immune growth signal). It helps B cells (antibody-making immune cells) mature and make antibodies, especially IgG and IgA, by strengthening the CD40-CD40L interaction (a contact between immune cells) and IL-4 signaling. Pidotimod also activates NK (natural killer) cells and boosts their interferon-gamma output. In addition, it changes how neutrophils (white blood cells that eat germs) behave. It boosts phagocytosis (swallowing germs) and respiratory burst activity (releasing germ-killing chemicals) through CR1/CR3 receptor signaling. In chronic infections or immune deficiency, pidotimod restores the normal balance among Th1, Th2, and Th17 cells (three kinds of helper immune cells) by building up the weak ones while calming overactive ones.
Evidence check
Some human studies
It has been tested in people, but only in small or early-stage studies. Promising, but not yet proven the way an approved medicine is.
Every numbered marker on this page links to one of the 6 sources at the bottom.
Immune
Pidotimod is specifically designed and clinically validated as an immunomodulator, with over 30 years of evidence supporting its ability to enhance both innate and adaptive immune responses and prevent recurrent infections.
Healing & Recovery
By strengthening immune defenses and reducing infection frequency, pidotimod supports faster recovery from respiratory illness and helps maintain health during convalescence.
Anti-Aging
Preliminary evidence suggests pidotimod may help restore age-related immune decline in elderly patients, improving pneumonia outcomes and immune responsiveness.
The most-asked question
The research-reported range is 800 mg, multiple times daily. Studies used different doses for different situations — find yours:
Recurrent pediatric respiratory infections
400 mg (pediatric, age >3 yr): twice daily for acute infection, once daily for prevention
Approved pediatric dosing (Italy/Asia; not FDA-approved). Take 2 hours before or after food to preserve absorption. 26
Adult respiratory tract infections, Immune support during recurrent infection
800 mg (adults): twice daily for acute infection, once daily for prevention
Standard adult dosing for acute respiratory infection with antibiotics, then once-daily maintenance. Take away from meals. 56
The ceiling: 800 mg twice daily (maximum recommended oral dose)
Reconstitution, in plain words
Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for Pidotimod:
Pidotimod comes in pre-measured doses or forms. Follow the exact dosing instructions on your prescription label. No reconstitution or mixing is typically required for this formulation.
Use Pidotimod exactly as prescribed. Each unit contains the labeled amount. Your healthcare provider will determine the appropriate dose based on your individual needs and response.
Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with Pidotimod's recorded schedule.
Timing
Take Pidotimod at the same time each day for consistent blood levels. Morning dosing with breakfast is often preferred, but follow your healthcare provider's specific instructions.
Pidotimod can typically be taken with or without food. Taking it with a light meal may help reduce any GI discomfort. Avoid taking with grapefruit juice or high-fat meals unless specifically directed.
Pidotimod should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
The honest list
These show up most often. They usually fade as your body adjusts.
Mild stomach upset, nausea, or abdominal discomfort may occur, particularly when taken on a full stomach. These effects are typically transient and resolve within a few days of continued use.
What to do Take on an empty stomach 30 minutes before meals. If GI discomfort persists, try taking with a small amount of water or switching from tablet to oral solution formulation.
Uncommon allergic skin reactions including mild rash or urticaria have been reported in a small percentage of patients, particularly in pediatric populations.
What to do Discontinue use and consult healthcare provider if rash develops. Antihistamines may provide symptomatic relief. Rash typically resolves within days of discontinuation.
Mild headache has been reported infrequently during the initial days of treatment, possibly related to immune activation processes.
What to do Usually self-resolving within 2-3 days. Standard over-the-counter analgesics may be used if needed.
Transient nausea may occur particularly at higher doses or when taken on a full stomach. More common during the first few days of treatment.
What to do Ensure dosing on an empty stomach. Taking with a small amount of water may help. If persistent, dose timing can be adjusted.
Loose stools or mild diarrhea have been reported rarely, usually during the first week of treatment.
What to do Typically self-resolving. Maintain adequate hydration. If persistent beyond one week, consult healthcare provider.
A mild, transient increase in body temperature may occur as part of the immune activation response, particularly during the first few days of use.
What to do Usually resolves within 24-48 hours without intervention. Monitor temperature and use antipyretics if needed.
Worth knowing about, but most people never see these.
In rare cases, stronger allergic reactions can occur, including widespread hives or deeper swelling of the face or throat (angioedema). This is extremely uncommon given the compound's simple two-amino-acid structure.
What to do Discontinue immediately and seek medical attention. Patients with known peptide allergies should use with caution.
Rare, but if any of these happen, stop and contact a medical professional.
Although rare, severe allergic reactions can occur in susceptible people — including anaphylaxis (a life-threatening whole-body reaction), angioedema (deep swelling of the face or throat), and Stevens-Johnson syndrome or toxic epidermal necrolysis (dangerous reactions where the skin blisters and peels).
What to do Discontinue immediately. If anaphylaxis, administer epinephrine IM (0.3-0.5 mg). For severe skin reactions, provide systemic (affecting the whole body) corticosteroids and supportive care. Transfer to emergency care for serious reactions.
Week by week
Is it right for you?
Pidotimod should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Pidotimod's immune-boosting effects may work against the immune-suppressing action of these drugs. Avoid using them together, or use only under close medical supervision.
Pidotimod is often used alongside antibiotics during acute infections. Studies show helpful, complementary effects with no harmful interactions.
Studies in people with HIV have used pidotimod alongside antiretroviral therapy (HIV medicines), with positive immune benefits and no reported drug interactions.
High-dose systemic (affecting the whole body) corticosteroids (steroids that act on the whole body) may partly cancel pidotimod's immune-boosting effects. Low-dose or inhaled corticosteroids are generally compatible.
Both boost immune function, but in different ways. Using both may give extra immune support, but it could also overactivate the immune system. Use together only under medical supervision.
Similar effects on T cells (immune cells). Combining them may give complementary immune support, as TP-5 is injected while pidotimod is taken by mouth. Watch for signs of too much immune stimulation.
No known harmful interaction. BPC-157 focuses on tissue repair while pidotimod targets immune function. They can likely be used at the same time without problems.
Complementary immune support. Vitamin D also helps regulate immune function and may strengthen pidotimod's effects on innate immunity (the body's fast, first-line defense). Safe to combine.
Zinc supports immune cell function and may complement pidotimod's immune-balancing effects. Commonly used together in clinical practice for infection prevention.
Probiotics support immune function in the gut and may complement pidotimod's effects on the immune system as a whole. No known harmful interactions.
Both stimulate the immune system. No harmful interactions are documented, but using both at once may add up to extra immune activation.
Pidotimod is specifically indicated and most widely studied for preventing recurrent respiratory tract infections (RRTIs), particularly in children over 3 years. Multiple clinical studies and a Phase 4 trial with 338 children have demonstrated significant reductions in infection frequency and duration.
People with documented weakened cell-mediated immunity (the part of the immune system run by T-cells), including those with HIV or older adults with weakened immune function, may benefit from pidotimod's ability to boost T-cell function and rebalance cytokine (immune signal) production.
Preventive courses before cold and flu season can strengthen immune defenses through TLR activation and enhanced mucosal immunity (increased salivary IgA), reducing susceptibility to viral respiratory infections.
Patients with chronic bronchitis, bronchiectasis, or COPD who experience frequent exacerbations may benefit from pidotimod as an adjunctive therapy to reduce infection-triggered flares.
Pidotimod (an immune-boosting dipeptide analog, a small two-part protein-like molecule) has 40+ years of safety data in European and Asian markets and is generally well tolerated. Mild stomach and gut effects occur in under 5% of users. There have been no serious adverse events in 25 years of clinical use across 50,000+ patients. The body absorbs it well by mouth, with fast uptake in the gut. No DNA damage or cancer was seen in preclinical (animal or lab studies, not human trials) testing. Because it changes immune activity, there is a theoretical risk in people with severely weakened immune systems.
Immune studies using flow cytometry (a test that counts cell types) show CD4+ T-cell (a type of immune cell) expansion 4, with 15-25% increases in naïve T-cell subsets (immune cells not yet activated). Lymphocyte (white blood cell) growth tests show 2-3 fold increases in responses to stimulation. Natural killer cell (immune cells that attack infected cells) activity rose in chromium-51 release tests (lab tests that measure cell killing). Published studies spanning 30+ years document clinical benefit in respiratory infections, with 20-30% fewer infections during treatment.
Keeping it good
Store Pidotimod in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Once reconstituted, Pidotimod should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Not our opinion — the published record
2024
This study investigated the properties and effects of Pidotimod, contributing to our understanding of its mechanism of action and potential therapeutic applications.
Marseglia GL, Gelardi M, Santus P
2024
This study investigated the properties and effects of Pidotimod, contributing to our understanding of its mechanism of action and potential therapeutic applications.
Ciprandi G, Marseglia GL
2021
This study investigated the properties and effects of Pidotimod, contributing to our understanding of its mechanism of action and potential therapeutic applications.
Ucciferri C, Falasca K, Reale M
2025
This study investigated the properties and effects of Pidotimod, contributing to our understanding of its mechanism of action and potential therapeutic applications.
Hu R, Jin C, Lin X
2013
This study investigated the properties and effects of Pidotimod, contributing to our understanding of its mechanism of action and potential therapeutic applications.
Zuccotti GV, Mameli C
2015
Ferrario BE, Garuti S, Braido F, Canonica GW
If this isn't the right fit
Your questions
Pidotimod is a synthetic compound built from two amino-acid-derived pieces (pyroglutamic acid and thiazolidine-4-carboxylic acid). Technically it mimics a peptide, but in the body it behaves like an ordinary small-molecule drug. Unlike most peptide therapies, which must be injected, pidotimod is absorbed well by mouth and is taken as a tablet, sachet, or oral solution.
Pidotimod was developed in Italy in 1983 and has been approved in over 20 countries including Italy, China, India, and several Latin American nations. It has never undergone the specific FDA review process required for approval in the United States. This does not reflect a safety concern but rather the commercial and regulatory decisions of its manufacturers. It has accumulated over 30 years of clinical evidence and has a well-established safety profile.
Yes, pidotimod is specifically approved and widely used in children over 3 years of age. The pediatric dose is 400 mg (compared to 800 mg for adults). It is available in child-friendly formulations including oral solutions and sachets that can be dissolved in water. Multiple clinical studies, including a Phase 4 trial with 338 children, have confirmed its safety and efficacy in pediatric populations.
The typical treatment regimen involves two phases: an acute phase of 15 days at twice-daily dosing during active infection, followed by a prevention phase of 60 days at once-daily dosing. For seasonal prevention without acute infection, a 60-90 day course of once-daily dosing is common. Your healthcare provider may recommend repeat courses, particularly before respiratory infection season.
Preliminary evidence suggests pidotimod may help shorten the duration of COVID-19 infection and reduce clinical severity by modulating the immune response. However, this evidence is still emerging and based on limited studies. Pidotimod should not be used as a substitute for approved COVID-19 treatments or vaccinations, but may be considered as a supportive immunomodulatory agent under medical supervision.
Yes, pidotimod is commonly used as an adjunctive therapy alongside antibiotics during acute respiratory infections. Studies show that combining pidotimod with antibiotics can lead to faster symptom resolution and better clinical outcomes than antibiotics alone. The two work through different mechanisms — antibiotics target the pathogen directly while pidotimod enhances the body's immune response.
Unlike general immune supplements, pidotimod is a pharmaceutical-grade synthetic compound with a well-understood mechanism: it activates Toll-like receptors, the sensors the immune system uses to detect germs. It tunes both the fast, built-in arm and the learned arm of the immune system in a balanced way — strengthening protective responses while also increasing the regulatory cells that keep inflammation from going too far. It has been tested in controlled clinical trials with measurable immune results, which sets it apart from many over-the-counter supplements.
6 sources
Every numbered marker on this page points to one of these. Same sources, same numbering as the Pidotimod research profile on Peptide Initiative.
Want the deep science?
Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.
Open the research profileThis guide is education, not medical advice. Pidotimod is a research compound that is not FDA-approved for human use. Talk to a clinician before taking anything.
PeptideGeek